Telix Pharmaceuticals: Solid Q1 As Pipeline And PSMA Franchise Drive Outlook

Telix Pharmaceuticals Limited delivered strong Q1 '26 results with $230M revenue, up 24% YoY, and reaffirmed FY26 guidance of $950–$970M, above consensus. Precision Medicine drove TLX growth, notably Illuccix and Gozellix, while the pipeline advanced with late-stage assets like TLX591 and regulatory milestones for imaging agents. TLX stock valuation reflects high future growth expectations: 3.6x forward EV/sales, steep P/E ratios, but consensus expects rapid earnings inflexion as the pipeline commercializes.